This made it the first medication approved specifically for this condition
The question of whether this translates directly to humans is still being studied, but the neuroanatomical overlap is significant
Osteoarthritis: weight + pain In people with obesity and knee osteoarthritis , once-weekly semaglutide 2.4 mg produced: Greater weight loss Significantly larger reductions in knee pain Improved function Obstructive sleep apnea (OSA) The SURMOUNT-OSA phase 3 trials showed that tirzepatide (Zepbound) in adults with obesity and moderate-to-severe OSA: Reduced the apneahypopnea index (AHI) Lowered body weight, hypoxic burden, hsCRP, and systolic BP Improved sleep-related patient-reported outcomes compared with placebo In December 2024, the FDA approved Zepbound as the first medication specifically indicated for moderate-to-severe OSA in adults with obesity , alongside diet and physical activity
Looking for rapid weight loss in Miami Beach
Obesity is a complex, chronic condition with significant health consequences, and management should always be guided by a qualified healthcare professional with access to your full medical history
and (2) the improvement of autism severity in patient treated for 6 mo with L-carnitine, they also concluded that subsequent studies will be welcome[41]